GSK's Shingrix vaccine maintains 79.7-82% efficacy.

GSK announced that long-term data from its blockbuster shingles vaccine, Shingrix, showed 79.7% efficacy in participants aged 50 and above, six to 11 years after vaccination, with efficacy remaining high at 82% at year 11 post-vaccination. The data comes from a long-term follow-up, late-stage trial that tracked participants for up to 11 years after initial vaccination.

April 17, 2024
5 Articles

Further Reading